lenvatinib for Hepatocellular Carcinoma

"In this article, a significant number of patients were treated off label, including glucocorticoids; however, the evidence supporting their use for cancer is weak. More research is needed to determine whether treating patients with cancer with glucocorticoids will result in long-term benefits (see "Treatment" section for further discussion). Other treatments used in cancer are salivary gland biopsy, immunotherapy, plasma exchanges, and rituximab. More study is needed to determine whether these therapies provide long-term benefits. Even though the majority of patients with cancer do not develop malignancy, the risk of malignancy warrants surveillance of patients with cancer for early detection of malignancies." - Anonymous Online Contributor

"Carcinoma can present in a wide variety of locations. The two most common sites are the stomach and colon. Carcinoma of these two areas have characteristic features. For instance, stomach carcinoma is more likely to be detected later in life, and usually presents in the proximal location. On the other hand, colorectal carcinoma, tends to present early in life, and tend to arise at the distal end of the colon. There are some common characteristics to these tumours, in that they are frequently well defined, and have a low frequency of metastases. As a result, lymph nodes containing these tumours are usually negative on routine histology." - Anonymous Online Contributor

"The lifetime risk of developing carcinoma is much higher in women than in men and rises exponentially with age. The incidence rate of carcinoma per 1,000 in the U.S. is 2.9 times higher among women than among men. The incidence rate increases with age; it is 6.3 times higher in women than in men after age 55, and 20.1 times higher after age 70. The lifetime risk of developing carcinoma is approximately 70% in women and 46% in men." - Anonymous Online Contributor

"Cancers are a group of cell-based cancers (tumors and malignant or precancer neoplasms) that are derived from tissue cells or from cancers that metastasize (spread) from elsewhere. Cancers form when a cell divides uncontrollably and becomes cancerous when it forms a tumor. Carcinomas form in epithelial and mesenchymal tissues and when they metastasize can form in various anatomical locations, including the bone, brain, liver, and lung. There are approximately one million new cases of cancer in the United States each year (over 400,000 cancer cases per year). Cancer causes a significant loss of life and a large monetary burden on the U.S. health care system." - Anonymous Online Contributor

"Although the majority of patients with carcinoma of the bladder can be cured with surgery, the cure rate for carcinoma of the prostate is very low, with most patients dying of the cancer within 18 months of onset. The cure of carcinoma of the bladder is most likely to occur if cancer has not spread beyond the bladder to the regional lymph nodes, the liver and lungs. As patients are put into immediate post-operative care, a proportion die of cardiopulmonary and neurological causes." - Anonymous Online Contributor

"Most common signs of carcinoma of the colon are colon polyps, bowel haemorrhage and/or melena. Other signs may include fatigue, weight loss and anal irritation or bleeding. Painless lower abdominal tumour can occur. All patients should be assessed for signs of colon cancer." - Anonymous Online Contributor

"The disease has a high mortality. The mortality seems higher in patients who also manifest other systemic diseases or in patients with advanced stage or in cases of carcinoma of the bronchus or larynx." - Anonymous Online Contributor

"We have provided a general overview of the risk of developing carcinoma. Individual risk predictions will be more appropriately provided with more accurate genetic and clinical information. Genetic counseling from a professional, such as an obstetrician-gynecologist or geneticist, who is knowledgeable about multiple hereditary syndromes, is recommended. A multidisciplinary approach to the patient, including physical examination, counseling, risk stratification, and genetic counseling with familial risk assessment, is recommended. The patient's motivation, desire to learn more about the risk, and [how to help manage it appropriately|managing it appropriately]] needs for such information to be well understood." - Anonymous Online Contributor

"Treatment with either VEE-3125 or DVP-2922 was shown to be significantly more effective than placebo. Conversely, the combination of VEE-3125 with chemotherapy had no further effect on PFS. Therefore, VEE-3125 or DVP-2922 can be considered as a first-line treatment in combination with chemotherapy unless additional treatment is not warranted." - Anonymous Online Contributor

"The safety profile of lenvatinib in non-small cell lung cancer is that of a standard cytotoxic therapy. Patients receiving the lenvatinib-based salvage regimen had better time to progression as well as PFS and OS compared to the standard chemotherapy-based salvage regimen. The OS benefit appears to be particularly pronounced in patients with KRAS WT tumors. Patients with KRAS WT tumors are particularly likely to have synchronous liver metastases at initiation of the lenvatinib-based salvage regimen. Patients with metastatic NSCLC may derive a similar benefit regardless of KRAS status." - Anonymous Online Contributor

"The majority of breast carcinoma spread by lymphatic or hematogenous routes, by two years after diagnosis. The majority of the remaining breast carcinoma spreads slowly by regional lymphatic routes, by four years after diagnosis." - Anonymous Online Contributor

"Lenvatinib inhibits Bcr-Abl kinase and shows broad anti-tumor activity against pediatric solid tumors. Lenvatinib shows promising activity in a small heterogenous group of pediatric solid tumors. Clin Cancer Res; 22(14); 3678-88. ©2016 AACR." - Anonymous Online Contributor